admin

Pharmacy Benefit Managers (PBMs) act as intermediaries between health systems, pharmacies, and drug manufacturers, intended to control drug costs through negotiated discounts. However, misaligned incentives, hidden spread pricing, and opaque rebate structures often transform them into significant cost drivers, draining financial resources from 340B Covered Entities and communities. This article examines the systemic issues embedded

Data sovereignty in 340B programs refers to the ability of healthcare covered entities to maintain absolute control, privacy, and ownership over their patient and pharmacy claims data while navigating an increasingly complex web of manufacturer restrictions and federal compliance tracking requirements. As pharmaceutical manufacturers demand more granular data, and as state and federal regulations continuously

340B eligibility requirements for covered entities are designed to ensure that only specific healthcare providers serving vulnerable populations can access discounted drugs. To qualify, an entity must be a federally qualified health center (FQHC), certain hospitals such as disproportionate share hospitals (DSH), children’s hospitals, or other HRSA-recognized safety-net providers. The entity must be officially registered

The 340B Drug Pricing Program is a U.S. federal program that allows eligible healthcare organizations to purchase outpatient drugs at significantly reduced prices. Because the program involves complex compliance and operational requirements, many hospitals conduct a 340B Program Health Check to evaluate risks, strengthen controls, and ensure their program is operating correctly. The program matters